BE2012C025I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2012C025I2 BE2012C025I2 BE2012C025C BE2012C025C BE2012C025I2 BE 2012C025 I2 BE2012C025 I2 BE 2012C025I2 BE 2012C025 C BE2012C025 C BE 2012C025C BE 2012C025 C BE2012C025 C BE 2012C025C BE 2012C025 I2 BE2012C025 I2 BE 2012C025I2
- Authority
- BE
- Belgium
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004048928 | 2004-02-25 | ||
US11/031,057 US7157584B2 (en) | 2004-02-25 | 2005-01-07 | Benzimidazole derivative and use thereof |
PCT/JP2005/003422 WO2005080384A2 (en) | 2004-02-25 | 2005-02-23 | Benzimidazole derivative and use as aii receptor antagonist |
Publications (1)
Publication Number | Publication Date |
---|---|
BE2012C025I2 true BE2012C025I2 (en) | 2024-08-08 |
Family
ID=34858222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE2012C025C BE2012C025I2 (en) | 2004-02-25 | 2012-06-07 |
Country Status (34)
Country | Link |
---|---|
US (3) | US7157584B2 (en) |
EP (3) | EP2119715B1 (en) |
JP (2) | JP4256852B2 (en) |
KR (1) | KR101080029B1 (en) |
CN (2) | CN100503605C (en) |
AR (2) | AR047972A1 (en) |
AT (2) | ATE370136T1 (en) |
AU (1) | AU2005214271B8 (en) |
BE (1) | BE2012C025I2 (en) |
BR (2) | BRPI0507984B8 (en) |
CA (1) | CA2557538C (en) |
CY (5) | CY1107008T1 (en) |
DE (3) | DE602005002030T2 (en) |
DK (3) | DK1718641T3 (en) |
ES (3) | ES2293552T3 (en) |
FR (1) | FR12C0034I2 (en) |
HR (3) | HRP20070510T3 (en) |
HU (1) | HUS1200008I1 (en) |
IL (1) | IL177533A (en) |
LU (1) | LU91962I2 (en) |
MA (1) | MA28478B1 (en) |
ME (2) | ME01089B (en) |
MY (1) | MY142807A (en) |
NL (1) | NL300802I2 (en) |
NO (2) | NO332344B1 (en) |
NZ (1) | NZ549755A (en) |
PL (3) | PL2119715T3 (en) |
PT (3) | PT1857457E (en) |
RS (3) | RS50537B (en) |
RU (2) | RU2369608C2 (en) |
SI (3) | SI1857457T1 (en) |
TW (1) | TWI336702B (en) |
WO (1) | WO2005080384A2 (en) |
ZA (1) | ZA200607241B (en) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7157584B2 (en) * | 2004-02-25 | 2007-01-02 | Takeda Pharmaceutical Company Limited | Benzimidazole derivative and use thereof |
CN102049048B (en) | 2004-12-24 | 2013-12-25 | 西芬克斯医药有限公司 | Method of treatment or prophylaxis |
JP4465469B2 (en) * | 2005-02-21 | 2010-05-19 | 国立大学法人佐賀大学 | Interleukin 13 as a cardiovascular disease marker |
US20090054502A1 (en) * | 2005-03-30 | 2009-02-26 | Takeda Pharmaceutical Company Limited | Benzimidazole Derivative and Use as Angiotensin II Antagonist |
WO2007097452A1 (en) * | 2006-02-27 | 2007-08-30 | Takeda Pharmaceutical Company Limited | Medical blister package |
WO2007097451A1 (en) * | 2006-02-27 | 2007-08-30 | Takeda Pharmaceutical Company Limited | Pharmaceutical package |
CA2646379C (en) | 2006-03-20 | 2014-12-23 | The University Of Queensland | Method of treatment or prophylaxis inflammatory pain |
ES2381507T3 (en) * | 2006-09-25 | 2012-05-28 | Takeda Pharmaceutical Company Limited | Medicinal container |
WO2008123536A1 (en) * | 2007-03-28 | 2008-10-16 | Takeda Pharmaceutical Company Limited | Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a ph control agent |
JP2009062296A (en) * | 2007-09-05 | 2009-03-26 | Fujifilm Corp | Method for producing carboxylic acid ester compound |
US20110038898A1 (en) * | 2008-03-13 | 2011-02-17 | Shuichi Yada | Dissolution properties of drug products containing olmesartan medoxomil |
MX2011001150A (en) * | 2008-07-31 | 2011-03-29 | Takeda Pharmaceutical | Solid pharmaceutical composition. |
TW201014850A (en) * | 2008-09-25 | 2010-04-16 | Takeda Pharmaceutical | Solid pharmaceutical composition |
CA2741125A1 (en) * | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US9387249B2 (en) | 2008-12-23 | 2016-07-12 | Takeda Pharmaceutical Company Limited | Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone |
US20110009347A1 (en) * | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
KR101931209B1 (en) | 2010-05-11 | 2018-12-20 | 얀센 파마슈티카 엔.브이. | Pharmaceutical formulations comprising 1-(beta-d-glucopyranosyl)-2-thienyl-methylbenzene derivatives as inhibitors of sglt |
WO2012090043A1 (en) | 2010-12-29 | 2012-07-05 | Jubilant Life Sciences Limited | Novel solid state forms of azilsartan medoxomil and preparation thereof |
US9233954B2 (en) | 2011-01-20 | 2016-01-12 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Organic amine salts of Azilsartan, preparation method and use thereof |
US9233955B2 (en) | 2011-02-08 | 2016-01-12 | Jubilant Life Sciences, Ltd. | Process for the preparation of azilsartan medoxomil |
CN102138899B (en) * | 2011-03-18 | 2013-08-21 | 海南本创医药科技有限公司 | Olmesartan liposome solid preparation |
RS55056B1 (en) | 2011-04-13 | 2016-12-30 | Janssen Pharmaceutica Nv | Process for the preparation of compounds useful as inhibitors of sglt2 |
CN102827153B (en) * | 2011-06-14 | 2016-10-05 | 江苏豪森药业集团有限公司 | Crystal formation of Azilsartan and preparation method thereof |
CN102351853B (en) * | 2011-08-29 | 2014-03-12 | 石药集团欧意药业有限公司 | Azilsartan medoxomil compound, preparation method and medicinal composition thereof |
WO2013042067A1 (en) | 2011-09-20 | 2013-03-28 | Ranbaxy Laboratories Limited | Process for the preparation of potassium salt of azilsartan medoxomil |
WO2013042066A1 (en) | 2011-09-20 | 2013-03-28 | Ranbaxy Laboratories Limited | Process for the preparation of azilsartan medoxomil |
BR112014014527A2 (en) | 2011-12-15 | 2017-06-13 | Takeda Pharmaceuticals Usa Inc | combinations of azilsartan and chlorotalidone to treat hypertension in black patients |
WO2013088384A2 (en) | 2011-12-15 | 2013-06-20 | Jubilant Life Sciences Limited | Solid state forms of azilsartan and azilsartan medoxomil monopotassium and preparation thereof |
CN104039779B (en) * | 2012-01-14 | 2016-08-24 | 广东东阳光药业有限公司 | Crystal formation of Azilsartan potassium and preparation method thereof and application thereof |
US20150011774A1 (en) * | 2012-02-02 | 2015-01-08 | Ranbaxy Laboratories Limited | Process for the preparation of azilsartan medoxomil or pharmaceutically acceptable salts thereof |
WO2013124748A1 (en) * | 2012-02-20 | 2013-08-29 | Alembic Pharmaceuticals Limited | Novel polymorphs of azilsartan medoxomil potassium |
CZ2012274A3 (en) * | 2012-04-19 | 2013-10-30 | Zentiva, K.S. | Process for preparing extremely pure potassium salt of azilsartan medoxomil |
WO2013186792A2 (en) * | 2012-06-11 | 2013-12-19 | Msn Laboratories Limited | Process for the preparation of (5-methyl-2-oxo-l,3-dioxoi-4-vl)methvl 2- ethoxv-l-{[2'-(5-oxo-4,5-dihvdro-l,2,4-oxadiazol-3-vl)biphenyi-4-vl]methyl}- lh-benzimidazole-7-carboxyiate and its salts |
WO2014009969A2 (en) * | 2012-07-09 | 2014-01-16 | Hetero Research Foundation | Novel polymorphs of azilsartan |
WO2014020381A1 (en) * | 2012-08-01 | 2014-02-06 | Alembic Pharmaceuticals Limited | Novel crystalline form of azilsartan medoxomil potassium |
EP2925753A4 (en) | 2012-08-27 | 2017-02-15 | Hetero Research Foundation | Novel polymorphs of azilsartan medoxomil |
WO2014049512A2 (en) | 2012-09-26 | 2014-04-03 | Lupin Limited | Novel process for preparation of azilsartan medoxomil |
CZ305318B6 (en) * | 2012-09-26 | 2015-07-29 | Zentiva, K.S. | Process for preparing extremely pure azilsartan medoxomil potassium salt |
CN105237527B (en) * | 2012-09-28 | 2018-03-06 | 武汉朗来科技发展有限公司 | Benzimidizole derivatives and preparation method thereof and medical usage |
AU2013329251A1 (en) * | 2012-10-09 | 2015-04-30 | Avery Dennison Corporation | Adhesives and related methods |
CN103910720A (en) * | 2013-01-07 | 2014-07-09 | 广东东阳光药业有限公司 | Novel crystal form of azilsartan medoxomil and preparation method thereof |
CN105153141B (en) * | 2013-02-04 | 2018-09-25 | 武汉朗来科技发展有限公司 | Benzimidizole derivatives and preparation method thereof and medical usage |
JP6281735B2 (en) * | 2013-03-19 | 2018-02-21 | トーアエイヨー株式会社 | Method for evaluating therapeutic agent for acute heart failure and method for producing acute heart failure model |
RU2535004C1 (en) * | 2013-06-11 | 2014-12-10 | Николай Андреевич Козлов | Method of treatment intervertebral disk disease in dogs |
RU2535005C1 (en) * | 2013-06-11 | 2014-12-10 | Николай Андреевич Козлов | Method of treatment of intervertebral disk diseases in dogs |
CN104812752B (en) * | 2013-10-12 | 2016-09-28 | 杭州领业医药科技有限公司 | Crystal form of azilsartan medoxomil and preparation method thereof |
CN105949183B (en) * | 2013-10-12 | 2019-02-22 | 杭州领业医药科技有限公司 | Crystal form of Azilsartan and preparation method thereof |
CN104774197B (en) * | 2014-01-09 | 2017-11-17 | 武汉朗来科技发展有限公司 | A kind of preparation method of benzimidizole derivatives |
CN104774196B (en) * | 2014-01-09 | 2017-11-10 | 武汉朗来科技发展有限公司 | A kind of preparation method of benzimidizole derivatives |
CN105079815A (en) * | 2014-04-30 | 2015-11-25 | 广东东阳光药业有限公司 | A kind of azilsartan medoxomil potassium composition and preparation method thereof |
CN104016974A (en) * | 2014-06-24 | 2014-09-03 | 浙江天宇药业股份有限公司 | Azilsartan medoxomil intermediates and synthetic methods thereof, as well as synthetic method of azilsartan medoxomil |
CZ2014702A3 (en) | 2014-10-15 | 2016-04-27 | Zentiva, K.S. | Process for preparing extremely pure azilsartan |
CN105622595A (en) * | 2014-11-21 | 2016-06-01 | 重庆朗天制药有限公司 | Novel preparation method of azilsartan medoxomil sylvite and its intermediate |
CN105753854A (en) * | 2014-12-16 | 2016-07-13 | 重庆朗天制药有限公司 | New preparation method of azilsartan kamedoxomil |
US9708306B2 (en) | 2015-03-18 | 2017-07-18 | Wuhan Ll Science And Technology Development Co., Ltd | Benzimidazole derivatives and preparation process and pharmaceutical uses thereof |
CN106032378B (en) * | 2015-03-20 | 2019-10-25 | 武汉启瑞药业有限公司 | New A RB compound and application thereof |
CN104803998B (en) * | 2015-03-26 | 2017-08-25 | 晋江市托美汀生物科技有限公司 | A kind of method for reducing impurity content |
JP2018521077A (en) * | 2015-07-29 | 2018-08-02 | タケダ ゲー・エム・ベー・ハーTakeda GmbH | PDE4 inhibitor for the treatment of diabetic nephropathy |
US20170071970A1 (en) | 2015-09-15 | 2017-03-16 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
JP6856365B2 (en) * | 2016-11-30 | 2021-04-07 | 株式会社トクヤマ | Manufacturing method of azilsartan |
CN109071519A (en) * | 2016-01-28 | 2018-12-21 | 株式会社德山 | Azilsartan and its manufacturing method |
CN105628824B (en) * | 2016-03-06 | 2017-10-17 | 江苏正大清江制药有限公司 | About the method for material in a kind of high effective liquid chromatography for measuring Azilsartan raw material |
CN112110909A (en) * | 2016-05-20 | 2020-12-22 | 武汉朗来科技发展有限公司 | Compound, preparation method, composition and application thereof |
CN105770876B (en) * | 2016-05-30 | 2019-09-10 | 广东天普生化医药股份有限公司 | Purposes of the ulinastatin in preparation treatment chronic prostatitis drug |
RU2623082C1 (en) * | 2016-07-11 | 2017-06-21 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Method for arterial rigidity correction in patients with rheumatoid arthritis |
EP3461822B1 (en) * | 2016-07-11 | 2022-11-02 | Wuhan LL Science And Technology Development Co., Ltd. | Crystalline form of chemical compound, and preparation method, composition, and application thereof |
RU2634272C1 (en) * | 2016-08-10 | 2017-10-24 | Закрытое акционерное общество "Санкт-Петербургский институт фармации" | Composition with desamino-arginine vasotocin for parenteral introduction and method for its production |
CN106074416A (en) * | 2016-08-30 | 2016-11-09 | 佛山市弘泰药物研发有限公司 | A kind of preparation method of Azilsartan potassium salt dispersible tablet |
FI3524250T3 (en) * | 2016-10-08 | 2025-08-29 | Wuhan Ll Science & Technology Development Co Ltd | Pharmaceutical composition comprising a neutral endopeptidase (nep) inhibitor and an azilsartan ester derivative and use thereof for treating cardiovascular diseases |
WO2019130277A1 (en) | 2017-12-30 | 2019-07-04 | Lupin Limited | Pharmaceutical formulations of azilsartan medoxomil |
CN110237071B (en) * | 2018-03-09 | 2022-03-22 | 武汉朗来科技发展有限公司 | Pharmaceutical preparation and use thereof |
CN110237072B (en) * | 2018-03-09 | 2022-03-25 | 武汉朗来科技发展有限公司 | Process for preparing pharmaceutical composition |
JP2021528735A (en) | 2018-06-14 | 2021-10-21 | アストラゼネカ・ユーケイ・リミテッドAstraZeneca UK Limited | Treatment of hypertension with angiotensin II receptor blocker pharmaceutical composition |
WO2019241519A1 (en) * | 2018-06-14 | 2019-12-19 | Astrazeneca Uk Limited | Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition |
KR20200057662A (en) | 2018-11-16 | 2020-05-26 | 엠에프씨 주식회사 | The derivative compounds of Azilsartan, intermediates thereof, preparation thereof and pharmaceutical composition comprising the same |
US11912688B2 (en) | 2019-02-15 | 2024-02-27 | Tohoku University | 1, 3-dioxolane derivative |
KR102220011B1 (en) | 2020-05-15 | 2021-02-25 | 대봉엘에스 주식회사 | Method for preparing azilsartan with environment-friendly solvent, and key intermediate compounds thereof |
CN113912580B (en) * | 2021-11-03 | 2023-06-02 | 瑞孚信江苏药业股份有限公司 | Method for purifying 4- (hydroxymethyl) -5-methyl- [1,3] dioxol-2-one |
TW202340183A (en) | 2021-12-28 | 2023-10-16 | 日商亞克醫藥股份有限公司 | Compound, angiotensin ii type 1 receptor antagonist and pharmaceutical composition |
EP4606374A1 (en) * | 2022-11-24 | 2025-08-27 | Shanghai Aurora Biotechnology Co., Ltd. | Pharmaceutical composition comprising azilsartan medoxomil potassium and calcium channel blocker, method for preparing same, and use thereof |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62290071A (en) | 1986-06-09 | 1987-12-16 | Matsushita Electric Ind Co Ltd | Organic electrolyne secondary battery |
US5196444A (en) | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
US5616599A (en) | 1991-02-21 | 1997-04-01 | Sankyo Company, Limited | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
IS1756B (en) | 1991-02-21 | 2000-12-28 | Sankyo Company Limited | Analogue method for the preparation of 1-biphenylmethylimidazole derivatives |
IL102183A (en) | 1991-06-27 | 1999-11-30 | Takeda Chemical Industries Ltd | Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them |
RU2117668C1 (en) * | 1991-10-23 | 1998-08-20 | Эйсаи Ко., Лтд. | Oxazolidone derivative or its pharmacologically acceptable salts, pharmaceutical composition, method of treatment |
US5310929A (en) | 1992-08-06 | 1994-05-10 | E. I. Du Pont De Nemours And Company | Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists |
JP2787539B2 (en) * | 1993-02-26 | 1998-08-20 | 松森 昭 | Agent for preventing or treating viral diseases |
FR2708612B1 (en) * | 1993-08-05 | 1996-03-01 | Roussel Uclaf | New bicyclic derivatives of imidazole, their preparation process, the new intermediates obtained, their application as medicaments and the pharmaceutical compositions containing them. |
TW403748B (en) * | 1994-11-02 | 2000-09-01 | Takeda Chemical Industries Ltd | An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same |
US5610314A (en) | 1995-04-03 | 1997-03-11 | Bristol-Myers Squibb Company | Process for preparing dioxolenone derivatives used for making prodrug esters and intermediates |
DE19707628A1 (en) * | 1997-02-26 | 1998-08-27 | Merck Patent Gmbh | Oxazolidinones |
CN1441794A (en) | 2000-07-13 | 2003-09-10 | 武田药品工业株式会社 | lipid-rich plaque reducer |
CA2468827A1 (en) | 2001-12-03 | 2003-06-12 | Takeda Chemical Industries, Ltd. | Insulin resistance improving agents |
AU2003202488A1 (en) | 2002-01-11 | 2003-07-30 | Takeda Pharmaceutical Company Limited | Coumarin derivatives, process for their production and use thereof |
US20070004736A1 (en) | 2002-11-22 | 2007-01-04 | Keiji Kubo | Imidazole derivative, process for producing the same, and use |
US6972258B2 (en) * | 2003-08-04 | 2005-12-06 | Taiwan Semiconductor Manufacturing Co., Ltd. | Method for selectively controlling damascene CD bias |
US7157584B2 (en) * | 2004-02-25 | 2007-01-02 | Takeda Pharmaceutical Company Limited | Benzimidazole derivative and use thereof |
JP4364171B2 (en) | 2005-07-15 | 2009-11-11 | 本田技研工業株式会社 | Automotive door checker |
-
2005
- 2005-01-07 US US11/031,057 patent/US7157584B2/en not_active Expired - Lifetime
- 2005-02-23 JP JP2005047294A patent/JP4256852B2/en not_active Expired - Lifetime
- 2005-02-23 SI SI200530822T patent/SI1857457T1/en unknown
- 2005-02-23 ES ES05719737T patent/ES2293552T3/en not_active Expired - Lifetime
- 2005-02-23 PL PL08075903T patent/PL2119715T3/en unknown
- 2005-02-23 RS RSP-2007/0448A patent/RS50537B/en unknown
- 2005-02-23 PT PT07075609T patent/PT1857457E/en unknown
- 2005-02-23 BR BRPI0507984A patent/BRPI0507984B8/en not_active IP Right Cessation
- 2005-02-23 ME MEP-2009-323A patent/ME01089B/en unknown
- 2005-02-23 PT PT05719737T patent/PT1718641E/en unknown
- 2005-02-23 RU RU2006133898/04A patent/RU2369608C2/en active Protection Beyond IP Right Term
- 2005-02-23 DK DK05719737T patent/DK1718641T3/en active
- 2005-02-23 EP EP08075903A patent/EP2119715B1/en not_active Expired - Lifetime
- 2005-02-23 DE DE602005002030T patent/DE602005002030T2/en not_active Expired - Lifetime
- 2005-02-23 WO PCT/JP2005/003422 patent/WO2005080384A2/en active Application Filing
- 2005-02-23 RS RSP-2009/0484A patent/RS51137B/en unknown
- 2005-02-23 RS RS20120362A patent/RS52376B/en unknown
- 2005-02-23 ES ES08075903T patent/ES2388945T3/en not_active Expired - Lifetime
- 2005-02-23 AR ARP050100653A patent/AR047972A1/en active IP Right Grant
- 2005-02-23 ES ES07075609T patent/ES2331209T3/en not_active Expired - Lifetime
- 2005-02-23 DK DK07075609T patent/DK1857457T3/en active
- 2005-02-23 CN CNB2005800130733A patent/CN100503605C/en not_active Expired - Lifetime
- 2005-02-23 PT PT08075903T patent/PT2119715E/en unknown
- 2005-02-23 KR KR1020067016710A patent/KR101080029B1/en not_active Expired - Lifetime
- 2005-02-23 DE DE602005016162T patent/DE602005016162D1/en not_active Expired - Lifetime
- 2005-02-23 AT AT05719737T patent/ATE370136T1/en active
- 2005-02-23 RU RU2009115498/04A patent/RU2501798C2/en active Protection Beyond IP Right Term
- 2005-02-23 AT AT07075609T patent/ATE440095T1/en active
- 2005-02-23 BR BR122012009489A patent/BR122012009489B8/en not_active IP Right Cessation
- 2005-02-23 EP EP07075609A patent/EP1857457B1/en not_active Expired - Lifetime
- 2005-02-23 SI SI200531568T patent/SI2119715T1/en unknown
- 2005-02-23 ME MEP-2007-448A patent/ME01643B/en unknown
- 2005-02-23 HR HR20070510T patent/HRP20070510T3/en unknown
- 2005-02-23 SI SI200530072T patent/SI1718641T1/en unknown
- 2005-02-23 PL PL05719737T patent/PL1718641T3/en unknown
- 2005-02-23 CN CN2008101701465A patent/CN101381366B/en not_active Expired - Lifetime
- 2005-02-23 NZ NZ549755A patent/NZ549755A/en not_active IP Right Cessation
- 2005-02-23 PL PL07075609T patent/PL1857457T3/en unknown
- 2005-02-23 AU AU2005214271A patent/AU2005214271B8/en not_active Expired
- 2005-02-23 EP EP05719737A patent/EP1718641B1/en not_active Expired - Lifetime
- 2005-02-23 MY MYPI20050690A patent/MY142807A/en unknown
- 2005-02-23 DK DK08075903.8T patent/DK2119715T3/en active
- 2005-02-23 CA CA2557538A patent/CA2557538C/en not_active Expired - Lifetime
- 2005-02-23 TW TW094105364A patent/TWI336702B/en active
-
2006
- 2006-08-16 IL IL177533A patent/IL177533A/en active IP Right Grant
- 2006-08-23 US US11/466,633 patent/US7572920B2/en not_active Expired - Lifetime
- 2006-08-30 ZA ZA2006/07241A patent/ZA200607241B/en unknown
- 2006-09-20 NO NO20064251A patent/NO332344B1/en active Protection Beyond IP Right Term
- 2006-09-22 MA MA29333A patent/MA28478B1/en unknown
-
2007
- 2007-11-14 CY CY20071101476T patent/CY1107008T1/en unknown
-
2008
- 2008-12-22 JP JP2008325152A patent/JP2009137974A/en active Pending
-
2009
- 2009-06-30 US US12/458,092 patent/US7875637B2/en not_active Expired - Lifetime
- 2009-11-04 HR HR20090593T patent/HRP20090593T1/en unknown
- 2009-11-12 CY CY20091101184T patent/CY1109610T1/en unknown
-
2012
- 2012-03-21 LU LU91962C patent/LU91962I2/en unknown
- 2012-03-29 DE DE201212000018 patent/DE122012000018I1/en active Pending
- 2012-05-11 FR FR12C0034C patent/FR12C0034I2/en active Active
- 2012-05-17 HU HUS1200008C patent/HUS1200008I1/en unknown
- 2012-05-31 CY CY2012016C patent/CY2012016I2/en unknown
- 2012-05-31 CY CY2012015C patent/CY2012015I1/en unknown
- 2012-06-07 BE BE2012C025C patent/BE2012C025I2/fr unknown
- 2012-08-17 HR HRP20120667TT patent/HRP20120667T2/en unknown
- 2012-08-29 CY CY20121100774T patent/CY1113084T1/en unknown
- 2012-11-09 NO NO2012017C patent/NO2012017I1/en not_active IP Right Cessation
-
2014
- 2014-01-27 AR ARP140100236A patent/AR094588A2/en not_active Application Discontinuation
-
2016
- 2016-03-15 NL NL300802C patent/NL300802I2/nl unknown